Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Other Working Capital Changes (2020 - 2025)

Tango Therapeutics has reported Other Working Capital Changes over the past 6 years, most recently at $3.6 million for Q4 2025.

  • Quarterly results put Other Working Capital Changes at $3.6 million for Q4 2025, up 508.85% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (up 182.38% YoY), and the annual figure for FY2025 was $1.8 million, up 182.38%.
  • Other Working Capital Changes for Q4 2025 was $3.6 million at Tango Therapeutics, up from -$2.3 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for TNGX hit a ceiling of $12.8 million in Q3 2021 and a floor of -$35.1 million in Q4 2023.
  • Median Other Working Capital Changes over the past 5 years was $386500.0 (2022), compared with a mean of -$1.5 million.
  • Biggest five-year swings in Other Working Capital Changes: surged 18229.77% in 2021 and later plummeted 24988.46% in 2024.
  • Tango Therapeutics' Other Working Capital Changes stood at -$4.3 million in 2021, then surged by 117.42% to $747000.0 in 2022, then plummeted by 4800.0% to -$35.1 million in 2023, then skyrocketed by 97.49% to -$881000.0 in 2024, then surged by 508.85% to $3.6 million in 2025.
  • The last three reported values for Other Working Capital Changes were $3.6 million (Q4 2025), -$2.3 million (Q3 2025), and $5.9 million (Q2 2025) per Business Quant data.